


Figure S1. N-CAFs and R-CAFs were exposed to the indicated concentrations of gemcitabine for 72h, and viability was measured via MTT assay. 3 biologic replicates were included in the experiment. ** $p \le 0.01$, **** $p \le 0.0001$






Figure S2. MiaPaCa-2 cells (1 X 10⁵) were subcutaneously injected with N-CAF cells expressing GFP (3 X 10⁵) in NSG mice. At 6 weeks, tumors were harvested and fluorescence microscopy was performed. Representative images of H&E stained sections as well as fluorescence microscopy are displayed. Only occasional GFP+ CAFs were present after 6 weeks.




Figure S3. Primary CAFs were treated with 1µM GEM plus DMSO or the above listed small molecule inhibitors for 96h and SASP mediator expression was compared to untreated cells via qRT-PCR. Because of limited primary cell numbers, the experiment was performed once in multiple cell lines rather than being replicated in any single line. Drug concentrations and targets: SB203580 10µM-P38 MAPK, SP600125 20µM- JNK, BEZ235 1µM- ATM/ATR/DNA-PK/PI3K/mTOR, AZD77622 200nM- Chk1/Chk2 VE821 2µM- ATR, KU55933 20µM-ATM.




Figure S4. Combined data from Figure S3. The mean normalized expression of each marker from CAF1-3 is displayed. In this combined analysis, none of the changes reached statistical significance.

Gene	Forward Primer	Reverse Primer
CXCL-1	AGGGAATTCACCCCAAGAAC	ACTATGGGGGATGCAGGATT
CXCL-6	AGAGCTGCGTTGCACTTGTT	GCAGTTTACCAATCGTTTTGGGG
ICAM-1	GCTGACGTGTGCAGTAATACTGG	TTCTGAGACCTCTGGCTTCGT
IL-1α	CGCCAATGACTCAGAGGAAGA	AGGGCGTCATTCAGGATGAA
IL-1β	AAACAGATGAAGTGCTCCTTCC	AAGATGAAGGGAAAGAAGGTGC
IL1R1	ATGAAATTGATGTTCGTCCCTGT	ACCACGCAATAGTAATGTCCTG
IL-6	AAAGAGGCACTGGCAGAAAA	AGCTCTGGCTTGTTCCTCAC
IL-8	ACTGAGAGTGATTGAGAGTGGAC	AACCCTCTGCACCCAGTTTTC
SPP1	GCCGAGGTGATAGTGTGGTT	TGAGGTGATGTCCTCGTCTG
RPL13	CATCGTGGCTAAACAGGTACTG	GCACGACCTTGAGGGCAGCC

Table S1. Primer sequences.